![Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/ddad2030-b355-4c6d-9487-4b9d1e28e855/gr1.jpg)
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases
![Global-first COVID-19 vaccine booster trial launches in Bradford – Bradford Teaching Hospitals NHS Foundation Trust Global-first COVID-19 vaccine booster trial launches in Bradford – Bradford Teaching Hospitals NHS Foundation Trust](https://www.bradfordhospitals.nhs.uk/wp-content/uploads/2021/06/vab.jpg)
Global-first COVID-19 vaccine booster trial launches in Bradford – Bradford Teaching Hospitals NHS Foundation Trust
![Washington University participates in clinical trial of Moderna omicron booster – Washington University School of Medicine in St. Louis Washington University participates in clinical trial of Moderna omicron booster – Washington University School of Medicine in St. Louis](https://medicine.wustl.edu/wp-content/uploads/GettyImages-1341059534_forweb-700x467.jpg)
Washington University participates in clinical trial of Moderna omicron booster – Washington University School of Medicine in St. Louis
![News - Major Covid-19 booster trial looks at how best to improve immunity against coronavirus in vulnerable people - University of Nottingham News - Major Covid-19 booster trial looks at how best to improve immunity against coronavirus in vulnerable people - University of Nottingham](https://www.nottingham.ac.uk/PressReleaseLongForm-Images/MHS/Vaccine-combo.xd02a85cc.jpg)
News - Major Covid-19 booster trial looks at how best to improve immunity against coronavirus in vulnerable people - University of Nottingham
![Major COVID-19 booster trial looks at how best to improve immunity against coronavirus in vulnerable people | NIHR Major COVID-19 booster trial looks at how best to improve immunity against coronavirus in vulnerable people | NIHR](https://www.nihr.ac.uk/images/news/booster-hero-image.png)
Major COVID-19 booster trial looks at how best to improve immunity against coronavirus in vulnerable people | NIHR
![Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial | Nature Medicine Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-01739-w/MediaObjects/41591_2022_1739_Fig1_HTML.png)
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial | Nature Medicine
![Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-02031-7/MediaObjects/41591_2022_2031_Fig1_HTML.png)
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine
![UC San Diego joins national trial to explore new vaccines for COVID-19 variants | University of California UC San Diego joins national trial to explore new vaccines for COVID-19 variants | University of California](https://www.universityofcalifornia.edu/sites/default/files/covid-vaccine-2022-trial.jpg)
UC San Diego joins national trial to explore new vaccines for COVID-19 variants | University of California
![Moderna on X: "In a Phase 2/3 trial in over 500 adults, mRNA-1273.222, induced significantly higher neutralizing antibody titers against BA.4/BA.5 compared to a booster dose of mRNA-1273. Read more: https://t.co/CPnxL03nZW https://t.co/ODihw6qtsQ" / Moderna on X: "In a Phase 2/3 trial in over 500 adults, mRNA-1273.222, induced significantly higher neutralizing antibody titers against BA.4/BA.5 compared to a booster dose of mRNA-1273. Read more: https://t.co/CPnxL03nZW https://t.co/ODihw6qtsQ" /](https://pbs.twimg.com/media/Fhhqz2NWAAInpLU.jpg)
Moderna on X: "In a Phase 2/3 trial in over 500 adults, mRNA-1273.222, induced significantly higher neutralizing antibody titers against BA.4/BA.5 compared to a booster dose of mRNA-1273. Read more: https://t.co/CPnxL03nZW https://t.co/ODihw6qtsQ" /
![New global vaccine trial launched to evaluate fractional COVID-19 booster shots - Murdoch Children's Research Institute New global vaccine trial launched to evaluate fractional COVID-19 booster shots - Murdoch Children's Research Institute](https://www.mcri.edu.au/images/news/shutterstock_1935309334_indo_vaccination_centre.jpg)